Skip to main navigation

About
Research & Development
Pipeline
Investors
Careers

Press Releases

Press Releases

Year

September 19, 2023

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

August 17, 2023

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

August 8, 2023

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

August 3, 2023

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

August 1, 2023

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

June 8, 2023

Revolution Medicines to Participate in Upcoming Investor Conferences

May 24, 2023

Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit

May 8, 2023

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

May 1, 2023

Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023

April 13, 2023

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 1 - 10 of 113

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2023 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063
CCPA Notice | Privacy Policy

Search Investor Relations